Long-Term Outcomes of Elagolix in Women With Endometriosis-Reference-Cited by-同舟云学术

Long-Term Outcomes of Elagolix in Women With Endometriosis

Published:2018-07 Issue:1 Volume:132 Page:147-160
ISSN:0029-7844
Container-title:Obstetrics & Gynecology
language:en
Short-container-title:

Author:

Surrey Eric,Taylor Hugh S.,Giudice Linda,Lessey Bruce A.,Abrao Mauricio S.,Archer David F.,Diamond Michael P.,Johnson Neil P.,Watts Nelson B.,Gallagher J. Chris,Simon James A.,Carr Bruce R.,Dmowski W. Paul,Leyland Nicholas,Singh Sukhbir S.,Rechberger Tomasz,Agarwal Sanjay K.,Duan W. Rachel,Schwefel Brittany,Thomas James W.,Peloso Paul M.,Ng Juki,Soliman Ahmed M.,Chwalisz Kristof

Publisher

Ovid Technologies (Wolters Kluwer Health)

Subject

Obstetrics and Gynecology

Reference19 articles.

1. Pathogenesis and pathophysiology of endometriosis;Burney;Fertil Steril,2012

2. Prevalence and symptomatic burden of diagnosed endometriosis in the United States: national estimates from a cross-sectional survey of 59,411 women;Fuldeore;Gynecol Obstet Invest,2017

3. Clinical practice. Endometriosis;Giudice;N Engl J Med,2010

4. World Endometriosis Society consensus on the classification of endometriosis;Johnson;Hum Reprod,2017

5. The burden of endometriosis: costs and quality of life of women with endometriosis and treated in referral centres;Simoens;Hum Reprod,2012

Cited by 102 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Endometriosis and In Vitro Fertilization;Medicina;2024-08-21

2. Medical management of endometriosis;Current Opinion in Obstetrics & Gynecology;2024-08-17

3. Development and Application of a Physiologically Based Pharmacokinetic Model for Elagolix in the Adult and Adolescent Population;Clinical Pharmacokinetics;2024-07-26

4. Impact of relugolix combination therapy on functioning and quality of life in women with endometriosis-associated pain;Fertility and Sterility;2024-06

5. Efficacy, tolerability, and bone density outcomes of elagolix with add-back therapy for endometriosis-associated pain: twelve months of an ongoing randomized phase 3 trial;American Journal of Obstetrics and Gynecology;2024-06